Burt M, Heelan R T, Coit D, McCormack P M, Bains M S, Martini N, Rusch V, Ginsberg R J
Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY.
J Thorac Cardiovasc Surg. 1994 Feb;107(2):584-8; discussion 588-9.
We designed a prospective study to evaluate the accuracy of magnetic resonance imaging in distinguishing a benign from a malignant adrenal mass in patients with otherwise operable non-small-cell lung cancer.
Potentially operable non-small-cell lung cancer was prospectively staged. If a unilateral adrenal mass was found by computed tomographic scanning, respiratory compensated and cardiac gated thin section magnetic resonance imaging of the adrenal glands was done. One radiologist interpreted the magnetic resonance imaging scan blinded and, on the basis of the relative signal strengths of the T1- and T2-weighted images, judged whether the adrenal mass was benign or malignant. The patients then underwent a percutaneous needle biopsy of the adrenal mass, if technically feasible. If the result of the needle biopsy was nondiagnostic or if the biopsy was not feasible, an adrenalectomy through a posterior approach was performed.
Twenty-seven patients with a unilateral adrenal mass entered the study-11 men and 16 women whose ages ranged from 42 to 75 years (median 58 years). Four patients had epidermoid and 23 adenocarcinoma of the lung. The clinical locoregional stage was I in 9, II in 1, IIIA in 16, and IIIB in 1. Twenty-five completed the magnetic resonance imaging procedure. Five adrenal masses (19%) were metastatic non-small-cell lung cancer (adenocarcinoma = 4, epidermoid = 1); 22 masses (81%) were benign (adenoma = 20, hyperplasia = 2). There were no significant differences in age, sex, histologic type, or locoregional stage between those with a benign versus a malignant mass. However, the malignant masses were significantly larger (3.8 +/- 1.9 cm; range 2.5 to 7.1; median 3.1) than the benign masses (2.0 +/- 0.4 cm, range 1.2 to 2.8; median 2.0) (p < 0.001). Among those having magnetic resonance imaging (n = 25), the technique correctly predicted a malignant mass in the four patients with a histologically confirmed metastasis from non-small-cell lung cancer. However, among the 21 histologically benign masses, the magnetic resonance imaging was interpreted as benign in 5, malignant in 14, and indeterminate in 2. Therefore, although the false-negative rate was 0%, the false-positive rate was 67%.
Most adrenal masses in patients with otherwise operable non-small-cell lung cancer are benign. Currently available magnetic resonance imaging methods cannot replace biopsy.
我们设计了一项前瞻性研究,以评估磁共振成像在鉴别可手术的非小细胞肺癌患者肾上腺肿块为良性或恶性方面的准确性。
对可能可手术的非小细胞肺癌进行前瞻性分期。如果通过计算机断层扫描发现单侧肾上腺肿块,则对肾上腺进行呼吸补偿和心脏门控薄层磁共振成像检查。一名放射科医生在不知情的情况下解读磁共振成像扫描结果,并根据T1加权和T2加权图像的相对信号强度判断肾上腺肿块是良性还是恶性。然后,如果技术可行,对肾上腺肿块进行经皮穿刺活检。如果穿刺活检结果无法诊断或活检不可行,则通过后入路进行肾上腺切除术。
27例单侧肾上腺肿块患者进入研究,其中男性11例,女性16例,年龄42至75岁(中位数58岁)。4例为肺鳞状细胞癌,23例为腺癌。临床局部区域分期为I期9例,II期1例,IIIA期16例,IIIB期1例。25例完成了磁共振成像检查。5例肾上腺肿块(19%)为转移性非小细胞肺癌(腺癌4例,鳞状细胞癌1例);22例肿块(81%)为良性(腺瘤20例,增生2例)。良性肿块与恶性肿块患者在年龄、性别、组织学类型或局部区域分期方面无显著差异。然而,恶性肿块(3.8±1.9 cm;范围2.5至7.1;中位数3.1)明显大于良性肿块(2.0±0.4 cm,范围1.2至2.8;中位数2.0)(p<0.001)。在进行磁共振成像检查的患者中(n = 25),该技术正确预测了4例经组织学证实为非小细胞肺癌转移的恶性肿块。然而,在21例组织学良性肿块中,磁共振成像检查结果为良性5例,恶性14例,不确定2例。因此,虽然假阴性率为0%,但假阳性率为67%。
可手术的非小细胞肺癌患者中的大多数肾上腺肿块是良性的。目前可用的磁共振成像方法无法替代活检。